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Abstract
Background: Pancreas cancer is one of most aggressive human cancers with the survival rate for patients with
metastatic pancreas cancer at 5-6 months. The poor survival demonstrates a clear need for better target
identification, drug development and new therapeutic strategies. Recent discoveries have shown that the role for
Notch pathway is important in both development and cancer. Its contribution to oncogenesis also involves
crosstalks with other growth factor pathways, such as Akt and its modulator, PTEN. The mounting evidence
supporting a role for Notch in cancer promotion and survival suggests that targeting this pathway alone or in
combination with other therapeutics represents a promising therapeutic strategy.
Results: Using a pancreas cancer tissue microarray, we noted that Jagged1, Notch3 and Notch4 are overexpressed
in pancreas tumors (26%, 84% and 31% respectively), whereas Notch1 is expressed in blood vessels. While there
was no correlation between Notch receptor expression and survival, stage or tumor grade, Notch3 was associated
with Jagged1 and EGFR expression, suggesting a unique relationship between Notch3 and Jagged1. Inhibition of
the Notch pathway genetically and with gamma-secretase inhibitor (GSI) resulted in tumor suppression and
enhanced cell death. The observed anti-tumor activity appeared to be through Akt and modulation of PTEN
phosphorylation. We discovered that transcriptional regulation of RhoA by Notch is important for PTEN
phosphorylation. Finally, the mTOR inhibitor Rapamycin enhanced the effect of GSI on RhoA expression, resulting
in down regulation of phospho-Akt and increased in vitro tumor cytotoxity.
Conclusions: Notch pathway plays an important role in maintaining pancreas tumor phenotype. Targeting this
pathway represents a reasonable strategy for the treatment of pancreas cancers. Notch modulates the Akt pathway
through regulation of PTEN phosphorylation, an observation that has not been made previously. Furthermore, we
discovered that this regulation is dependent on RhoA/Rock1 activation. Enhanced phospho-Akt suppression when
GSI is combined with rapamycin suggests that targeting both pathways will lead to a greater efficacy in the
treatment of patients with pancreas cancer.
Background
The Notch pathway is an evolutionarily conserved path-
way important for cell fate determination in development
as well as in cancer. In development, Notch is involved in
tissue patterning and morphogenesis through cell differ-
entiation, proliferation and apoptosis. The Notch family
in mammals consists of four receptors (Notch1-4) and
five ligands (Jagged1, 2 and Delta-like 1, -3, -4). In the
canonical pathway, Notch receptors are activated by
membrane-bound ligands, resulting in several intramem-
brane proteolytic cleavages that untether the cytoplasmic
domain (NICD) from the cytoplasmic membrane. The
NICD translocates to the nucleus and activates the tran-
scription of target genes, such as those belonging to the
Hairy/enhancer of split and Hairy/enhancer of split-
related with YRPW motif families [1]. In cancer, Notch
crosstalks with numerous oncogenic pathways, such as
Akt, TGF-b and src signaling [2-4]. In certain context,
the interaction between Notch and other oncogenic
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activation [5].
While accounting for only 4% of estimated new cases of
cancer in both men and women, pancreas cancer is the
fourth leading cause of cancer-related death in the United
States [6]. The median survival for patients with advanced
pancreas cancer remains at 5-6 months, a rate that has not
changed significantly over the last decade [7]. Thus, identi-
fication of new targets is needed to improve clinical out-
come. Current literature suggests that Notch pathway
plays an instrumental role in pancreas cancer. In the
developing pancreas, Notch regulates the ratio between
the exocrine and endocrine cell mass, supporting its role
in controlling cell-fate determination [8]. RT-PCR showed
that Notch pathway components were overexpressed in a
small set of pancreas tumors. Furthermore, activated
Notch cooperates with TGF-b in the expansion of undif-
ferentiated precursor cells and in the promotion of PanIN
progression to anaplastic pancreas cancer [9,10].
In this study, we examined the prevalence of Notch
receptors and ligands in a large number of patients with
pancreas cancers. Using immunohistochemistry (IHC) on
a tissue array, we discovered that Notch3 was most often
overexpressed in pancreas cancer, followed by Notch4.
Conversely, Notch1 was expressed in the vasculature
within the tumor mass but not in malignant cells. Further-
more, inhibiting Notch activation reduced tumor pheno-
types and Akt phosphorylation in pancreas cancer. While
previous studies have shown that Notch-dependent activa-
tion of Akt is a result of transcriptional downregulation of
PTEN, we noted that in our system, Notch regulated
PTEN phosphorylation but not PTEN expression. Our
results show that this regulation is dependent on RhoA
and Rock1, an observation that has not been previously
described. Finally, rapamycin, an inhibitor of the mTOR
pathway, greatly enhanced Notch-dependent inhibition of
Akt and tumor cytoxicity in vitro. This effect appears to
be dependent of RhoA. Taken together, our observations
further support a role for Notch in pancreas cancer and
suggest a new strategy in targeting pancreas cancer.
Results and Discussion
Notch Receptors and Ligands Are Expressed in Resected
Pancreas Cancer
T h ep r e v a l e n c ei ne x p r e s s i o no fap o t e n t i a lo n c o g e n e
helps determine the significance of its role in cancer. To
better understand the role of Notch pathway in pancreas
cancer, we developed a pancreas tissue microarray with
associated clinical data from 86 patients (Table 1). We
also examined the expression of Notch1-4 and their
ligands, Jagged1 and DLL4. Notch3 was most prevalent
with greater expression in 84% of resected cancers, fol-
lowed by Notch4 at 31% (Table 2 Figure 1). Interestingly,
none of the tumor cells expressed Notch1, and only one of
the 86 tumors surveyed expressed Notch2. Notch1 and
DLL4 were expressed predominantly in endothelial cells,
suggesting that, while not significantly expressed in tumor
cells, they are important in tumor angiogenesis. We also
Table 1 Patients’ Characteristics
n (%)
Age Median 66
Range 37-84
< 65 39 (45)
≥ 65 38 (44)
Gender Male 48 (56)
Female 38 (44)
Race White 81 (94)
Black 2 (2)
Unkown 3 (3)
Tumor Size ≤ 1 cm 4 (5)
> 1 and ≤ 2 cm 21 (25)
> 2 and ≤ 3 cm 30 (36)
> 3 cm 28 (34)
pT T1 1 (1)
T2 7 (8)
T3 75 (88)
T4 1 (1)
pN Yes 46 (54)
No 39 (46)
pM Yes 5 (6)
No 81 (94)
Stage IA & IB 3 (3)
IIA 33 (38)
IIB 44 (51)
III 1 (1)
IV 5 (6)
Tumor Grade 1 17 (20)
2 34 (40)
3 35 (41)
Chemotherapy Yes 30 (35)
No 32 (37)
Unknown 24 (28)
Pos-Op XRT Yes 21 (24)
No 39 (45)
Unknown 26 (30)
Table 2 Expression of Notch receptors and ligands in
resected pancreas cancer
Grade DLL4 Jagged1 Notch3 Notch4
n7 1 7 3 7 5 7 0
12 4 9 6
21 8 2 4 8
36 7 3 0 8
Total 9 19 63 22
% Positivity 13 26 84 31
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family members and clinical characteristics, such as overall
survival, stage and tumor grade. No association between
Notch receptors and clinical characteristics was observed.
However, we noted that Notch3 expression correlated
with Jagged1, but not for Delta-like 4, suggesting that
Jagged1 is the ligand for Notch3 (Figure 1C, Table 3) [11].
Of note, eighty-five percent of the tumors surveyed with
IHC exhibited high expression of EGFR (Figure 1B).
Notch3 also correlates with EGFR expression (Figure 1D,
Table 4), consistent with our previous finding in lung can-
cer that Notch3 and EGFR pathways cooperate in main-
taining the oncogenic phenotype [12]. Notch receptors are
activated by proteolytic cleavages after ligand binding,
resulting in the release of the cytoplasmic domain (NICD).
We were able to demonstrate that several human pancreas
cancer cell lines expressed the activated forms or NICD of
Notch receptors (Figure 2A). In addition, pancreas cancer
cell lines developed from overexpressing K-rasG12D and
TGF-b knockout mice showed Notch1 ICD and Notch3
ICD expression (Figure 2B), further supporting the role of
Notch pathway in pancreas cancers [13]. Similar to our
previous observation, Jagged1 is also highly expressed in
nearly all of cell lines tested [14]. We found no difference
in Notch expression between cell lines with K-ras muta-
tion alone (K162, K512, K518) and those with both
K-rasG12D and TGF-b knockout (K375, K389, K399).
Figure 1 Expression of Notch Receptors and Ligands in Pancreas Cancer. (A) Representative examples of some pancreas tumors expressing
Delta-like 4 (DLL4), Jagged1(J1), Notch3 (N2), Notch3 (N3), and Notch4 (N4) by IHC. No tumor expressed Notch1 (N1), but its expression can be
detected in blood vessels (arrow). (B) A representative example of a pancreas tumor expressing high level of EGFR. While the expression of
Notch ligands and receptors does not correlate with clinical characteristics, Notch3 expression correlates positively with that of Jagged1 (C) and
that of EGFR (D).
Table 3 Pearson’s Correlation between Jagged and Notch 3
Notch3
Jagged1 0 1 2 3 Total
0 451 86 3 3
1 0 1 7 12 20
2 0 2 871 7
3 0 0 112
Total 483 42 67 2
p-value = 0.01039
Table 4 Pearson’s Correlation between EGFR and Notch 3
Notch3
EGFR 0 1 2 3 Total
1 3 4 311 1
2 041 27 2 3
3 002 01 93 9
Total 383 52 77 3
p-value = 4.799e-07
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secretase inhibitor, dose-dependent down regulation of
activated Notch3 was observed (Figure 2C). Interestingly,
while we observed suppression of the activated form of
Notch, we observed a rise in HES1 and HEY1 transcripts,
suggesting that Notch modulates cancer phenotype in
pancreas through non-canonical pathways (Figure 2D, E).
Inhibiting Notch Activation Reduces Malignant Phenotype
and Induces Apoptosis
To determine whether inhibiting Notch activation reduces
tumor phenotype, we utilized both dominant-negative
Notch3 receptor and a g-secretase inhibitor (GSI). When
BxPc3 was transfected with dominant-negative Notch3 or
treated with 25 μM of MRK003, colonies were significantly
reduced in number, as compared to vector controls (VC)
or DMSO control (C) (Figure 3A). A significant body of
literature has supported a role for Notch signaling in
apoptosis. Similar to our previous observation in lung can-
cer, inhibiting Notch in serum-free condition resulted in
enhanced cancer cell death measured with PI staining
(Figure 3B). The Bcl-2 family plays an important role in
apoptosis through the activation of the mitochrondria-
dependent caspase pathway. Using Notch3 siRNA, we
showed that Notch regulates Bcl-xL expression and Bcl-2
(Figure 3C). When MRK003 was used, a similar effect on
Bcl-xL could be found, accompanied by an increase in
cleaved PARP, a marker of caspases activation (Figure 3D).
To determine whether g-secretase inhibitors possess activ-
ity in vivo, we inoculated xenografts with K162 and K399
cell lines developed from a mouse model of pancreas can-
cer. The g-secretase inhibitors DAPT and MRK003 sup-
pressed tumor growth by 25% to 50%, suggesting that the
Notch pathway plays a role in the survival of cancer cells
in both in vitro and in vivo models (Figure 3E).
GSI Inhibits Akt Activation and PTEN Phosphorylation
The Notch pathway is known to crosstalk with other
oncogenic pathways such as the EGFR and the Akt path-
way [12,15]. Interestingly, unlike observations in lung can-
cer, inhibition of the Notch pathway in pancreas cancer
had no appreciable effect on ERK activation (Figure 4A).
On the other hand, Akt phosphorylation was inhibited by
MRK003 in pancreas cancer cell line K399. PTEN (phos-
phatase and tensin homolog) is a well-known negative reg-
ulator of Akt. In hypoxia, Notch1 has been shown to
Figure 2 Notch Receptors are Expressed in Pancreas Cancer Cell Lines, and Their Inhibition Is Inde-pendent of The Canonical Pathway.
(A) As opposed to resected pancreas cancers, expression of all four NICDS or activated forms of the Notch receptors can be seen in the human
pancreas cancer cell lines. Both BxPC-3 and Panc-1 cell lines also express Jagged1. (B) Murine pancreas cell lines, developed from mice
overexpressing K-rasG12D and TGF-b knockout, express only Notch1 ICD and Notch3 ICD. There was no appreciable difference in Notch
expression K162, K152, and K518. (C) Inhibition of Notch3 using the g-secretase inhibitor MRK003 resulted in the loss of activated Notch3. (D, E)
However, enhanced transcription of Notch-dependent genes HES1 and HEY1 determined with RT-PCR suggests that the effect of Notch
inhibition on pancreas cancer cells is not through the Notch canonical pathway.
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[15]. However, while Notch is known to regulate Akt
through the transcriptional regulation of PTEN, we did
not detect a difference in total PTEN levels. Rather the
phosphorylation of PTEN at Ser380 was altered, when GSI
was used (Figure 4A). While not much is known about the
phosphorylation of PTEN, recent evidence suggests that it
regulates protein stability [16]. While some findings indi-
cate that phosphorylation of PTEN improves stability but
reduces PTEN function, others have shown that the loss
of phospho-PTEN in migrating cells leads to the activation
of Akt [17]. Cdc42, a member of the Rho GTPase family,
is important in Akt-mediated cell survival and motility,
and its activation is inhibited by PTEN [18,19]. We noted
a decrease in Cdc42 when treated with GSI, suggesting
that Notch regulates Akt-dependent cell survival through
PTEN and Cdc42.
How PTEN is regulated through phosphorylation is
intensely investigated. In a recent model of chemotaxis pro-
posed by Li et al., Rock1, a member of the Rho-associated,
coiled-coil containing protein kinases, is activated by Rho-
GEF (guanine nucleotide-exchange factor) and RhoA,
another Rho GTPase family member. Activated Rock1 then
binds and phosphorylates PTEN [17,20]. Rho proteins and
Rock proteins are important regulators of cell migration,
proliferation and apoptosis [21]. To examine the role of the
Figure 3 Inhibition of Notch Pathway Results in the Loss of Tumor Phenotype and a Decrease in Proliferation. (A) Inhibition of Notch
signaling pathway using the dominant-negative Notch3 receptor (DN) and MRK003 markedly reduces the size of the colonies formed in soft
agar of pancreas cancer cell line BxPC3, compared with control. (B) Similar to our previous observation in lung cancer, inhibition of Notch
pathway using the DN receptor enhances cancer cells dependency on exogenous growth factor. Cells transfected with the DN construct shows
a higher death rate in 0% serum, measured using PI staining, compared to control and cells grew in 10% fetal calf serum (FCS). (C). Using siRNA,
loss of Notch3 reduces expression of Bcl-2 family proteins such as Bcl-xL and Bcl-2 in BxPC3. (D) A similar result is obtained when the g-secretase
inhibitor MRK003 is used. Loss of Bcl-xL also coincides with the increase in cleaved PARP, a measure of apoptosis. (E) Both g-secretase inhibitors
DAPT (10 mg/kg i.p.) and MRK003 (100 mg/kg, given through oral gavage in 3 consecutive days/week) attenuate tumor growth in K399 and
K162 subcutaneous xenograft models.
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lation in pancreas cancer, we examined the effect of GSI on
Rock1 and RhoA. Interestingly, we noted an increase in the
expression of RhoA with increasing dose of GSI, whereas
the expression of Rock1 remained essentially unchanged
(Figure 4B). The effect of Notch signaling on RhoA appears
to be transcriptionally mediated (4C). To determine
whether Notch modulation of PTEN phosphorylation is
dependent on RhoA/Rock1, we examined the effect of GSI
in the presence of Rock1 inhibitor Y27632 (4D). Whether
the observations in the chemotaxis model can be translated
into a cancer model requires further validation. The loss of
PTEN phosphorylation by GSI in the presence of Y27632
suggests, however, that the Notch effect on PTEN depends
on the RhoA/Rock1 pathway.
Rapamycin Enhances GSI Antitumor Activity Through the
Regulation of Akt
The observed redundancy in oncogenic pathways may
require that multiple pathways are inhibited in order to
enhance tumor cytotoxicity. The PI3K/Akt/mTOR path-
way is activated in the majority of pancreas cancers.
Because of the crosstalk between Notch and Akt, we
examined whether the combination of the mTOR inhibi-
tor Rapamycin and MRK003 will result in improved
tumor cytotoxicity. While some studies suggest that Rapa-
mycin induces Akt activation, we noted that in K399 rapa-
mycin inhibits Akt phosphorylation, and that this
inhibition was enhanced, when Rapamycin was combined
with MRK003 [22] (Figure 5A). Again, we observed a
change in phospho-PTEN, but not total PTEN, when
Figure 4 Notch Inhibition Results in Downregulation of Akt Activation Through Rho-Dependent PTEN phosphorylation.( A )N o t c h
inhibition with MRK003 led to a decrease in Akt phosphorylation, but not ERK phosphorylation in K399. While the level of PTEN did not change
with MRK003 treatment, expression of pPTEN was enhanced. Cdc42, a down-stream target of PTEN was also reduced. (B) MRK003 induced
expression of the PTEN regulator, RhoA, but not Rock1. (C) Transcription of RhoA was induced 1.5× with MRK003, suggesting that the induction
of RhoA by Notch inhibition is transcriptionally mediated. (*) denotes statistical significance compared with control. (D) This induction of
phospho-PTEN was ameliorated in the presence of Rock1 inhibitor Y27632 at 30 μM (lanes 4 and 5), suggesting that Notch’s effect on
phosphoPTEN depends on the Rock/Rho pathway.
Vo et al. Molecular Cancer 2011, 10:138
http://www.molecular-cancer.com/content/10/1/138
Page 6 of 10Notch pathway is inhibited. Furthermore, the level of
phospho-PTEN was increased when MRK003 was com-
bined with rapamycin. Foxo3a is a member of the fork-
head family which acts as tumor suppressor by promoting
cell cycle arrest and apoptosis. It is inactivated by Akt. The
combination of Rapamycin and MRK003 led to a slight
increase in the tumor suppressor Foxo3a and pro-apopto-
tic Bim, a member of the BH-3 only Bcl-2 family. More-
over, we noted an increased expression of RhoA, when
cancer cells were treated with MRK003, and the change
was enhanced when Rapamycin was added (Figure 5B).
No change in Rock1 level was detected. Taken together,
these observations support the hypothesis that Notch and
mTOR cooperate in regulating Akt through PTEN phos-
phorylation and RhoA.
Notch Inhibition Enhanced Rapamycin-dependent Growth
Suppression in pancreas Cancer Cells
While results from preclinical studies using mTOR inhibi-
tors in pancreas cancers have been promising, their low
efficacy in early clinical studies indicate that these agents
possess minimal clinical activity when administered as sin-
gle agents [23]. Redundancy in the biological system and
results from clinical trials suggest that targeting multiple
targets will result in augmented tumor suppression.
Because we observed Akt suppression when GSI was
added to Rapamycin, we tested whether inhibiting the
Notch pathway will enhance tumor suppression with
mTOR inhibitor in vitro. In both human and murine pan-
creas cell lines, K399 and Panc-1, respectively, the combi-
nation of MRK003 and rapamycin inhibited proliferation
to a greater degree than Rapamycin or MRK003 alone
(Figure 5C, D). These findings suggest that Notch can
enhance Rapamycin in inhibiting pancreas cancer growth
through the modulation of Akt.
Conclusions
Overexpression of Notch receptors and ligands in pan-
creas cancer supports the hypothesis that this develop-
mental pathway plays an important role in this type of
cancer. However, the lack of correlation between Notch
pathway compounds, clinical characteristics and outcome
does not support their use as biomarkers.We observed
that Notch3 is expressed in cancer cells, whereas Notch1
is mainly expressed in blood vessels. Differences in
expression pattern among the various Notch pathway
components suggest a non-redundancy in functions. We
hypothesize that in cancer Notch3 is important for
tumor survival, whereas Notch1 mediates the response to
hypoxia through the regulation of angiogenesis. This
hypothesis is supported by previous observations from
other investigators [12,15,24]. Furthermore, our observa-
tions suggest that a less specific Notch inhibitor will be
more effective for targeting cancer cells and the tumor
microenvironment, albeit with higher toxicity profile.
However, only further clinical testing can ascertain this
supposition.
While none of the Notch receptors have been shown to
be useful as biomarkers, our in vitro and in vivo data pro-
vide evidence that the Notch pathway is oncogenic. Tar-
geting this pathway genetically or with small molecules
such as g-secretase inhibitors may reduce tumor pheno-
type and represent a viable option for the treatment of
patients with pancreas cancer. Because of the redundancy
in oncogenic signals, targeting multiple Notch pathways
will likely improve clinical outcomes. Similar to Notch, the
Figure 5 Notch Modulates Akt Activation and Cooperates with mTOR Inhibitor in Tumor Proliferation. (A) Akt inactivation and PTEN
phosphorylation by Rapamycin (10 μM) are enhanced when MRK003 (10 μM) is added. MRK003 also enhances induction of pro-apoptic Fox3a
and Bim by the mTOR inhibitor rapamycin. (B) Notch inhibition results in higher expression of RhoA, and the induction of RhoA is enhanced
when rapamycin was combined with MRK003. No change is observed with Rock1. (C, D) In the MTT survival assays, the combination of MRK003
and rapamycin also leads to higher tumor cytoxicity in vitro, compared to either agents alone, in both murine K399 and human Panc-1 pancreas
cancer cell lines.
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processes, including cell growth, proliferation, and survival
[25]. Furthermore, Akt is found to be activated in 59% of
tumors. Our findings demonstrate that Notch modulates
Akt, supporting a crosstalk between the pathways. While
the mechanisms for this crosstalk needs further elucida-
tion, our data suggest that one mechanism involves the
modulation of PTEN phosphorylation.
PTEN is a tumor suppressor and functions as a phos-
phatidylinositol phosphate (PIP) phosphatase. Depho-
sphorylation of PI(3,4,5)P3 by PTEN prevents the
phosphorylation and activation of Akt kinase [26]. Earlier
studies suggest that, while phosphorylation of PTEN at the
C2 domain enhances PTEN stabilization, it also promotes
a closed conformation, inhibiting PTEN activity [16,27].
Conversely, in inflammatory cells, Rock1 was found to
bind to PTEN and is essential for PTEN phosphorylation
and activation [20]. Bone marrow cells from mice lacking
functional Rock1 showed loss of PTEN activity and
increased Akt activation [17]. Thus, similar to many com-
plex biological systems, the phenotypic outcome of PTEN
and RhoA/Rock pathways activation is highly context
dependent.
In our system, we observed no difference in Rock1
expression with GSI, but RhoA expression was enhanced.
RhoA is a member of the Rho family of small GTPases. It
is required for Rock1 activation [20]. The Notch-depen-
dent increase in PTEN phosphorylation is inhibited by
Rock1 inhibitor, suggestingt h a tN o t c hr e g u l a t e sP T E N
through the RhoA/Rock1 pathway. Our study is the first
to show that Notch regulates the phosphorylation of
PTEN through the RhoA pathway in pancreas cancer.
We have demonstrated that the Notch pathway plays an
important role in pancreas cancer. Furthermore, our find-
ings suggest thst a cooperative relationship between the
Notch pathway and the Akt/mTOR pathway may exist
and this interaction is mediated by the Rho GTPase path-
way. Similar to Notch, other studies have indicated a con-
tradictory role of Rho proteins in cancer, suggesting that
its role is highly context dependent. However, from the
treatment perspective, Notch can be considered a target
for intervention, since the inhibition of this pathway miti-
gates the malignant phenotype. Moreover, due to the
crosstalk with the mTOR pathway, combination treatment
may improve therapeutic outcome.
Methods
Cell lines, Constructs and Inhibitors
Human pancreas cancer cell lines Panc-1, HRAF-II and
BxPC3 were obtained from American Type Culture Col-
lection (ATCC). Murine pancreas cancer cell lines K399,
K389, K375, K162, K152, and K518 were developed ex
vivo from tumors of mice overexpressing K-rasG12D and
TGF-b knockout, and were obtained from Dr. H. Moses
[13]. The formulation and the in vivo dosing schedule of
g-secretase inhibitor MRK003 were provided by Merck
Co., Inc, and were described previously [28]. The mTOR
inhibitor rapamycin and the Rock1 inhibitor Y27632 were
obtained from Sigma-Aldrich and CalBiochem, respec-
tively. The g-secretase inhibitor DAPT (N-[N-(3,5-Difluor-
ophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), was
also obtained from Sigma-Aldrich. The dominant-negative
Notch3 (DN) and VC (control) constructs were trans-
fected into BxPC3 and selected with G418, as previously
described [12]. Notch3 siRNA3 sequences were also
described previously [14].
TMA Construction, TMA Slide Preparation
De-identified tumor and adjacent normal tissues were
obtained under an IRB-approved protocol at Vanderbilt
University Medical Center. Before constructing a TMA
block, serial 5-μm sections were cut from each donor
block. One of these sections was stained with H&E for
marking morphologically representative areas of the
tumor. Using a Beecher Instruments Tissue Arrayer (Silver
Springs, MD), tissue cylinders with a diameter of 0.6 mm
were punched from the four targeted areas in each donor
block and deposited into a 9 × 14 (~126 cores) TMA
block, which contained 76 cores of adenoma tissue and 50
cores of adjacent, non-malignant tissue as controls. The
TMA blocks were warmed to 36°C for 30 minutes, and
multiple serial 5 μm sections were cut and placed on
charged slides.
Antibodies
The Notch3 antibody 1E4 (a gift from Dr. Anne Joutel)
was used for immunohistochemistry, and the method
was described previously [29]. Jagged1 (C-20) and
Notch4 (H-225) were purchased from Santa Cruz,
whereas Notch1 (3608), DLL4 (HPA023392) and Notch2
(C651.6D6HN) antibodies were obtained from Cell Sig-
naling Technology, Sigma-Aldrich, and the Developmen-
tal Studies Hybridoma Bank (DSHB), respectively.
Human EGFR antibody (31G7) was purchased from
Zymed. The IHC staining was scored on a composite
scale of 0 to 3 by two independent observers, including
one pathologist. In case of disagreement, the decision
was deferred to the pathologist. The tumors that scored 2
or better were considered positive. For immunoblotting,
Notch1 (3447), Notch3 (2889), phospho-Akt, total Akt,
PTEN, pPTEN, RhoA, Rock1, cdc42, Bcl-xL, Bcl-2 and
PARP were obtained from Cell Signaling Technology.
For specific use in murine cell lines, Jagged1 (H114),
Notch1 (C-20), and Notch3 (M-134) were obtained from
Santa Cruz, and Notch2 (C651.6D6HN) and Notch4
were purchased from DSHB and Orbigen, respectively.
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Total RNA was isolated from K399 cells using Sure Prep
RNA Purification Kit (Fisher Scientific). cDNA synthesis
was carried out using iScript cDNA Synthesis Kit, accord-
ing to manufacturer’s recommendation (Bio Rad). Primers
for murine GAPDH were AATGGGGTGAGGCCGGTG
(sense) and CAGAAGGGGCGGAGATGATG (antisense).
Murine RhoA primers were CCATGTACCCAAAAGC
GCC (sense) and CAAATGTGCCCATCGTCCTG (anti-
sense). Experiments were performed at annealing tempera-
ture of 55°C for 39 cycles.
Proliferation Assays, Soft Agar and Cell Death Analysis
Cells were plated into 96-well microtitre plates at 10% FCS
and at 50% confluency in 200 μl DMEM. After 48 hours
of treatment with inhibitors, 50 μlo fM T T( 3 - ( 4 , 5 -
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
stock solution (2 mg/ml) was added to each well, and the
plates were incubated for 4 hours. MTT formazan crystals
were then resolubilized by adding 150 μl1 0 0 %d i m e t h y l -
sulfoxide (DMSO) to each well. Plates were agitated on a
plate shaker for 5 min, and the absorbance at 540 nm was
determined using a scanning multi-well spectrophot-
ometer (BioRad). For soft agar assays, transfected cells
were plated at a density of 5000 cells/plate using 35 mm
Petri dishes and suspended in 0.4% agar containing 10%
FCS RPMI and 50 μg/ml of G418 selective antibiotic over
0.8% base agar. The plates were incubated at 37°C and 5%
CO2 in a humidified chamber for 14 days. Cell death was
determined as follows: Cells were stably transfected with
Notch3 DN or treated with MRK003 for 24 hours and
were maintained in 10% FCS-RPMI or serum-free med-
ium. Then, they were stained with propidium iodide (Cal-
biochem, La Jolla, CA). The percentage of dead cells was
determined with a Beckman Coulter FACS Calibur Flow
Cytometer.
In Vivo Tumorigenicity
Animal experiments were performed according to the
protocol approved by Vanderbilt University IACUC.
A t h y m i c4 - t o6 - w e e k - o l df e m a l en u d em i c e( n u + / n u + )
were used for the tumor xenograft models. Panc1 or
K399 (1 × 106 cells in the volume of 200 ml of PBS) was
inoculated subcutaneously (s.c.) into the right posterior
legs of nude mice. Treatment was initiated when tumors
were palpable. MRK-003 (150 mg/kg) was administered
orally for three consecutive days per week for 2 weeks.
MRK-003 was diluted in 0.5% methylcellulose. The
tumors were measured every 2 days with a caliper.
Tumor Volume (TV) was calculated with the formula:
TV = (Length) × (Width)2/2. Percentage tumor volume
(% TV) on day X was calculated as: %TV = (tumor
volume on day ×/tumor volume on day 1) × 100.
Statistical Analyses
The size of implanted tumors at precise time points after
treatment was compared with that of control groups.
Unless specifically stated, statistical inference in all com-
parative experiments both in vivo and in vitro was
obtained using unpaired, two-sided Student’s t-tests. For
TMA, protein expression was correlated using Pearson’s
correlation coefficients. For all determinations, differ-
ences were considered significant at P < 0.05.
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